Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select™ in China
December 07 2018 - 9:00AM
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth
diagnostics company, today announced regulatory acceptance of the
T-Cell Select kit by the China Food and Drug Administration (CFDA).
The T-Cell Select kit was designed as an immune cell separation
reagent kit to simplify workflow, improve throughput, and reduce
hands-on time and labor costs in performing the T-SPOT®.TB test.
With the T-Cell Select kit, blood samples collected in a single
standard blood tube can be stored for up to 54 hours at room
temperature before use, further extending the company’s unrivaled
simplicity and logistics advantages for customers.
For additional information, please visit:
http://www.oxfordimmunotec.com/international/products-services/t-cell-select/.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics
company focused on developing and commercializing proprietary
assays for immunology and infectious disease. The Company's
T-SPOT.TB test has been approved for sale in over 50 countries,
including the United States, where it has received pre-market
approval from the Food and Drug Administration, Europe, where it
has obtained a CE mark, as well as Japan and China. The Company is
headquartered near Oxford, U.K. and in Marlborough, MA.
Additional information can be found at www.oxfordimmunotec.com.
T-SPOT, T-Cell Select and the Oxford Immunotec logo are
trademarks of Oxford Immunotec Ltd.
Forward-Looking Statements
This release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this release are
forward-looking statements. This includes statements about Oxford
Immunotec's anticipated plans and objectives, future performance
and revenues, financial condition, prospects for sales of its
products, growth, strategies, expectations and objectives of
management. Forward-looking statements can be identified by the
fact that they do not relate strictly to historical or current
facts. Forward-looking statements contained in this release reflect
Oxford Immunotec's current expectations and are subject to risks
and uncertainties. Actual results may differ materially from those
projected or implied by forward-looking statements. Other factors
that could adversely affect Oxford Immunotec's business and
prospects are described under the "Risk Factors" section in its
filings with the Securities and Exchange Commission ("SEC"). Oxford
Immunotec's SEC filings are available for free by visiting the
investor section of its website, www.oxfordimmunotec.com, or the
SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and
uncertainties. Forward-looking statements contained herein are
based on current expectations and assumptions and currently
available data and are neither predictions nor guarantees of future
events or performance. Investors should not place undue reliance on
forward-looking statements contained herein, which speak only as of
the date of this release. Oxford Immunotec does not undertake to
update or revise any forward-looking statements after they are
made, whether as a result of new information, future events, or
otherwise, except as required by applicable law.
CONTACTS:
For Media and Investor Inquiries: Karen
KoskiVP, Strategy and Investor RelationsOxford ImmunotecTel: +1
(508) 556-1377kkoski@oxfordimmunotec.com
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Apr 2023 to Apr 2024